IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury [0.03%]
IGFBP4是原发性胆汁性胆管炎的标志物并能减轻肝细胞损伤
Xing Zhou,Shuyu Shao,Danning Yang et al.
Xing Zhou et al.
Background and aims: Immune-mediated bile duct injury is the primary histological feature of autoimmune cholestatic liver diseases. Macrophages, the most abundant immune cell population in the liver, have been postulated ...
Practical Considerations for MRI-Derived Retreatment Response Scores in Viable HCC [0.03%]
可用于肝癌亚治疗反应评分的MRI实际考量因素
Yicheng Huang,Zichen Yu
Yicheng Huang
Ziyan Pan,Shadi Zerehpoosh,Mohammed Eslam
Ziyan Pan
GDF-15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes [0.03%]
肝硬化患者中的GDF-15水平与肝脏纤维化、细菌移位以及更差的临床结局相关
Benedikt Silvester Hofer,Thomas Perkmann,Ksenia Brusilovskaya et al.
Benedikt Silvester Hofer et al.
Background &aims: Growth differentiation factor-15 (GDF-15), a cell stress-induced cytokine, is implicated in liver disease pathophysiology. We investigated GDF-15 in cirrhosis, focusing on its association with disease-dr...
Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk [0.03%]
APOB变异导致的低胆固醇：探究肝脏和心血管风险之间的平衡
Alessia Di Costanzo,Ilaria Pirona,Silvia Buonaiuto et al.
Alessia Di Costanzo et al.
Background & aims: Lifelong APOB gene inactivation lowers LDL-C and cardiovascular risk, but impairs hepatic lipoprotein export, predisposing to chronic liver disease (CLD). The extent to which common steatogenic factors ...
MASLD in Adults With Type 1 Diabetes and Type 2 Diabetes Undergoing Vibration-Controlled Transient Elastography [0.03%]
振动控制瞬时弹性成像检测的1型糖尿病和2型糖尿病成人患者的肝脂肪变性
Alessandro Mantovani,Enrico Scoccia,Riccardo Morandin et al.
Alessandro Mantovani et al.
Background: There is limited evidence on the prevalence of, and factors contributing to, metabolic dysfunction-associated steatotic liver disease (MASLD) among individuals with type 1 (T1DM) and type 2 (T2DM) diabetes mel...
Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta-Analysis [0.03%]
与肝硬化相比，严重纤维化患者向去补偿期进展的系统评价和meta分析
Rachael Barrett,Annie Archer,Jennifer Cathcart et al.
Rachael Barrett et al.
Background & aims: Metabolic associated steatotic liver disease (MASLD) is increasing in prevalence worldwide. Clinical practice is focused on identifying those with cirrhosis and monitoring for complications such as vari...
Do We Still Need a BCLC-Intermediate Stage for Hepatocellular Carcinoma-Management? [0.03%]
我们还需要肝细胞癌管理的BCLC中期分期吗？
Markus Peck-Radosavljevic
Markus Peck-Radosavljevic